Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Why this topic
- Risk-benefit analysis
- Adverse drug event/reaction
- Adverse event assessment
- Adverse event classification: descriptive types
- Adverse event classification: mechanisms
- Adverse event classification: by targets
- Factors involved in adverse events
- ADR: epidemiology
- ADR: reporting
- Take-home messages
Topics Covered
- Drug toxicity
- Adverse Drug Events (ADE) and Adverse Drug Reactions (ADR)
- Drug use risk-benefit analysis
- Adverse event assessment and classifications
- Factors involved in drug adverse events
- ADR epidemiology and reporting
Talk Citation
Allegaert, K. (2024, October 31). Drug toxicity: mechanisms, interactions, and adverse drug reactions [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 13, 2024, from https://doi.org/10.69645/JEAN8031.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose. However, off label use of medicines is discussed.
Other Talks in the Series: Key Concepts: Fundamentals of Pharmacology
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to this short
lecture on drug toxicity,
mechanisms, interactions, and
adverse drug reactions.
I'm Karel Allegaert.
I'm a clinical pharmacologist
located at KU Leuven.
0:16
Why would we discuss this topic?
Well, it's simply because
drugs, unfortunately,
do not only have effects
but also side effects.
These are commonly mentioned on
the leaflet or on the label,
and some specific
events like AKI,
DILI, or allergy are hereby
specifically highlighted.
AKI stands for acute
kidney injury.
DILI stands for
drug-induced liver injury.
There are high-risk drugs and
there are high-risk
subpopulations.
It's important to discriminate
between adverse drug events,
which are time-related events,
to adverse drug reactions,
which do have also a
connotation on causality,
so really, causally
related to the drug.
This means that we have to
consider causality assessment
and related to that also,
seriousness, and severity.
There are quite some
different mechanisms
involved and we will provide
some classifications.
An important message
to healthcare
providers is that we need
a reporting ecosystem.
We have to report on
adverse drug reactions.
Whether we are doctors,
nurses, pharmacists, midwives,
or whoever is involved
in this ecosystem,
as well obviously as
patients and their families.
1:36
As I already
somewhat alluded to,
drug use is a balanced decision
between efficacy and safety.
Depending on the severity
or the seriousness
of the disease,
people will generally accept
a lower safety profile
for instance if you treat
an oncological disease,
you will accept
that you may have
risks associated with
such treatments.
If we consider the definitions,